FDA Grand Rounds – Jan. 13, 2022

Join Us for the Upcoming FDA Grand Rounds Seminar!

If your email program has trouble displaying this email, view as a webpage. Development and Testing of Warnings for Tobacco Products: Scientific and Regulatory Considerations An image of a scientist holding a test tube. Thursday, January 13, 2022 12:00 p.m. - 1:00 p.m. EST Webcast About the Speaker David Portnoy, PhD Supervisory Social Scientist Division of Population Health Science (DPHS) Office of Science (OS) Center for Tobacco Products (CTP) David Portnoy is Chief of the Social Science Branch 2 in the Division of Population Health Science, Office of Science at the FDA Center for Tobacco Products. He has a MA and PhD in Social Psychology from the University of Connecticut and an MPH from the Johns Hopkins Bloomberg School of Public Health.  Dr. Portnoy completed post-doctoral training through the National Cancer Institute's Cancer Prevention Fellowship Program. In his current role, he leads a branch of Social Scientists focused on consumer perceptions and use of tobacco products, understanding communications about the harms of tobacco products (including warnings), and understanding and preventing youth use of tobacco products. His research interests include health risk perception and communication, consumer perceptions and use of tobacco products, and social psychological influences on health behavior and decision making. Dr. Portnoy was FDA's scientific lead for the research to support a new cigarette health warnings rule starting in 2013. About the Presentation Warnings inform consumers about risks and are required on many FDA-regulated products. They are especially important for products which have inherent and unavoidable risks associated with their use, such as tobacco products. This presentation will discuss the current regulatory landscape of tobacco product warnings through CTP's authority. We will examine the development and testing of warnings for cigarettes that resulted in the March 2020 final rule "Required Warnings for Cigarette Packages and Advertisements" with a focus on the scientific and regulatory considerations that went into that research and development plan for those warnings.  For more information and to register for this event visit www.FDA.gov/GrandRounds

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA